Nomura Holdings’s Intellia Therapeutics NTLA Stock Holding History

Nomura Holdings’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-49,900	Closed	-$449K	–	1993
2025 Q4	$449K	Sell	49,900 -20,000	-29%	-$275K	﹤0.01%	1564
2025 Q3	$1.21M	Buy	69,900 +49,900	+250%	+$615K	﹤0.01%	1333
2025 Q2	$188K	Sell	20,000 -20,000	-50%	-$164K	﹤0.01%	1308
2025 Q1	$284K	Buy	+40,000	New	+$404K	﹤0.01%	1613

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Nomura Holdings's NTLA Position: Q1 2026 in Review

Nomura Holdings sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 10,995 shares — an estimated $98.8K sold.

Nomura Holdings first reported a position in NTLA in Q2 2020 and held it in 11 quarters. The position peaked at $38.9M in Q1 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

Nomura Holdings reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
Nomura Holdings sold 10,995 Intellia Therapeutics shares in Q1 2026, an estimated $98.8K.
Nomura Holdings first reported a position in Intellia Therapeutics in Q2 2020 and held it in 11 quarters.
Nomura Holdings's Intellia Therapeutics position peaked at $38.9M in Q1 2021.
303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.